Home

Sarepta Therapeutics, Inc. - Common Stock (SRPT)

78.75
-22.60 (-22.30%)

Sarepta Therapeutics is a biotechnology company focused on pioneering innovative gene therapies for the treatment of rare genetic diseases, particularly those affecting muscle disorders

The company is dedicated to developing therapies that can enable patients with conditions like Duchenne Muscular Dystrophy to achieve improved outcomes and quality of life. With a strong emphasis on research and development, Sarepta utilizes advanced techniques such as RNA-targeted therapies and gene editing to combat genetic disorders at their source. Through its work, the company aims to transform the landscape of genetic medicine and provide hope for individuals and families affected by these challenging diseases.

SummaryNewsPress ReleasesChartHistoricalFAQ
Previous Close101.35
Open78.62
Bid78.65
Ask78.85
Day's Range75.06 - 81.87
52 Week Range97.06 - 173.25
Volume8,789,918
Market Cap7.34B
PE Ratio (TTM)33.65
EPS (TTM)2.3
Dividend & YieldN/A (N/A)
1 Month Average Volume1,093,115

News & Press Releases

12 Health Care Stocks Moving In Tuesday's Intraday Sessionbenzinga.com
Via Benzinga · March 18, 2025
Why Sarepta Therapeutics (SRPT) Shares Are Sliding Today
Shares of biotech company Sarepta Therapeutics (NASDAQSRPT) fell 24.9% in the pre-market session after the company reported the death of a Duchenne muscular dystrophy patient following treatment with its gene therapy, ELEVIDYS. The patient reportedly suffered acute liver failure, a known risk of AAV-mediated gene therapies. However, Sarepta suggested that a recent cytomegalovirus (CMV) infection might have worsened the condition. Despite this, the company maintained that ELEVIDYS still had a favorable benefit-risk profile. It planned to update the prescribing information and inform regulators, clinical investigators, and prescribing physicians of the incident. 
Via StockStory · March 18, 2025
Discover the top movers in Tuesday's pre-market session.chartmill.com
Discover the top movers in Tuesday's pre-market session and stay informed about market dynamics.
Via Chartmill · March 18, 2025
8 Analysts Have This To Say About Sarepta Therapeuticsbenzinga.com
Via Benzinga · February 27, 2025
Earnings Scheduled For February 26, 2025benzinga.com
Via Benzinga · February 26, 2025
2 Growth Stocks to Buy Hand Over Fist in Februaryfool.com
Via The Motley Fool · February 9, 2025
Sarepta Therapeutics Reports Patient Death Post Elevidys Gene Therapy Treatment, Stock Plungesbenzinga.com
Sarepta shares fell after reporting a patient death linked to Elevidys. The case involved acute liver failure, with a CMV infection as a potential factor.
Via Benzinga · March 18, 2025
Sarepta Therapeutics Plummets 23% After Gene Therapy Recipient Diesinvestors.com
The patient also had a recent CMV infection, which the company said could have contributed.
Via Investor's Business Daily · March 18, 2025
12 Health Care Stocks Moving In Tuesday's Pre-Market Sessionbenzinga.com
Via Benzinga · March 18, 2025
Arrowhead Pharmaceuticals Stock Falls After Early-Stage Data From RNA-Based Therapeutic For Kidney Diseasesbenzinga.com
Arrowhead's ARO-C3 cut C3 levels by up to 89% and proteinuria by 41% in a Phase 1/2 trial. Additional results will be presented at a 2025 medical meeting.
Via Benzinga · March 10, 2025
Spotting Winners: Sarepta Therapeutics (NASDAQ:SRPT) And Therapeutics Stocks In Q4
As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the therapeutics industry, including Sarepta Therapeutics (NASDAQSRPT) and its peers.
Via StockStory · March 4, 2025
What 14 Analyst Ratings Have To Say About Sarepta Therapeuticsbenzinga.com
Via Benzinga · January 15, 2025
SAREPTA THERAPEUTICS INC (NASDAQ:SRPT) showing high EPS and FCF growth while beating expectationschartmill.com
A fundamental analysis of (NASDAQSRPT): SAREPTA THERAPEUTICS INC NASDAQ:SRPTNASDAQSRPT)
Via Chartmill · March 4, 2025
Sarepta Therapeutics Announces Call for Applications for the 8th Annual Route 79, The Duchenne Scholarship Program
Sarepta Therapeutics, Inc. (NASDAQSRPT), the leader in precision genetic medicine for rare diseases, today announced the official opening of Route 79, The Duchenne Scholarship Program for the 2025-2026 academic year. Academic scholarships of up to $5,000 will be awarded to as many as 20 individuals living with Duchenne muscular dystrophy and 5 siblings of individuals living with Duchenne.
By Sarepta Therapeutics, Inc. · Via Business Wire · February 28, 2025
Sarepta Therapeutics (SRPT) Q4 2024 Earnings Call Transcriptfool.com
SRPT earnings call for the period ending December 31, 2024.
Via The Motley Fool · February 26, 2025
Sarepta Therapeutics’s (NASDAQ:SRPT) Q4: Beats On Revenue
Biotech company Sarepta Therapeutics (NASDAQSRPT) announced better-than-expected revenue in Q4 CY2024, with sales up 65.9% year on year to $658.4 million. Its non-GAAP profit of $1.90 per share was 7.8% below analysts’ consensus estimates.
Via StockStory · February 26, 2025
Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results and Recent Corporate Developments
Sarepta Therapeutics, Inc. (NASDAQSRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the fourth quarter and full-year 2024.
By Sarepta Therapeutics, Inc. · Via Business Wire · February 26, 2025
10 Health Care Stocks Whale Activity In Today's Sessionbenzinga.com
Via Benzinga · February 26, 2025
Sarepta Therapeutics (SRPT) To Report Earnings Tomorrow: Here Is What To Expect
Biotech company Sarepta Therapeutics (NASDAQSRPT) will be reporting results tomorrow after the bell. Here’s what you need to know.
Via StockStory · February 25, 2025
Solid Biosciences Soars 32% on Trial Data: 189% Upside from Here?
Solid Biosciences just saw a 32% move to the upside after its trial results impressed. What's next for this firm that analysts still see massive potential in?
Via MarketBeat · February 19, 2025
10 Health Care Stocks With Whale Alerts In Today's Sessionbenzinga.com
Via Benzinga · February 14, 2025
Sarepta Therapeutics Announces Inaugural $600 Million Senior Secured Revolving Credit Facility
Sarepta Therapeutics, Inc. (NASDAQSRPT), the leader in precision genetic medicine for rare diseases, announced today that it has closed on a $600 million senior secured revolving credit facility with a bank syndicate.
By Sarepta Therapeutics, Inc. · Via Business Wire · February 14, 2025
Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2024 Financial Results
Sarepta Therapeutics, Inc. (NASDAQSRPT), the leader in precision genetic medicine for rare diseases, will report fourth quarter and full-year 2024 financial results after the Nasdaq Global Market closes on Wednesday, Feb. 26, 2025. Subsequently, at 4:30 p.m. E.T., the Company will host a conference call to discuss its fourth quarter and full-year 2024 financial results.
By Sarepta Therapeutics, Inc. · Via Business Wire · February 12, 2025
Sarepta Therapeutics' Duchenne Gene Therapy Shows Sustained Benefits And Disease Stabilization At Two Yearsbenzinga.com
Sarepta's EMBARK study confirms Elevidys offers sustained Duchenne treatment benefits, including motor function improvement and minimal muscle pathology progression.
Via Benzinga · January 27, 2025
Sarepta Therapeutics Announces Results from Part 2 of the EMBARK Study Demonstrating Sustained Benefits and Disease Stabilization in Ambulatory Individuals with Duchenne Muscular Dystrophy Following Treatment with ELEVIDYS
Sarepta Therapeutics, Inc. (NASDAQSRPT), the leader in precision genetic medicine for rare diseases, today announced positive topline results from Part 2 of EMBARK (Study SRP-9001-301), a global, randomized, double-blind, placebo-controlled, Phase 3 clinical study of ELEVIDYS (delandistrogene moxeparvovec-rokl), the only approved gene therapy in patients with Duchenne muscular dystrophy.
By Sarepta Therapeutics, Inc. · Via Business Wire · January 27, 2025